Skip to main content
profile image
Selected Works of Philip Mease, MD
Article
169 Secukinumab provides sustained reduction in fatigue in patients with active psoriatic arthritis through three years: long-term data from the FUTURE 1 and FUTURE 2 studies
Rheumatology (2018)
  • Hector Chinoy, University of Manchester
  • Laure Gossec, University of Paris
  • Tore K Kvien, University of Oslo
  • Philip G Conaghan, University of Leeds
  • Mikkel Østergaard, Rigshospitalet
  • Dafna Gladman, Toronto Western Hospital
  • Philip Mease, University of Washington
  • Lawrence Rasouliyan, RTI International
  • Luminita Pricop, Novartis
  • Corine Gaillez, Novartis
  • Steffen Jugl, Novartis
Link
Disciplines
Publication Date
April 1, 2018
DOI
10.1093/rheumatology/key075.393
Citation Information
Hector Chinoy, Laure Gossec, Tore K Kvien, Philip G Conaghan, et al.. "169 Secukinumab provides sustained reduction in fatigue in patients with active psoriatic arthritis through three years: long-term data from the FUTURE 1 and FUTURE 2 studies" Rheumatology Vol. 57 (2018)
Available at: http://works.bepress.com/philip-mease/10/